GW Pharmaceuticals plc (NASDAQ: GWPH ) (OTC:GWPRF) developed the first marijuana-derived pharmaceutical to be approved by the FDA. Epidiolex, which contains CBD, was designed to treat Dravet syndrome and was the first drug ever approved to treat this rare form of epilepsy in the U.S. Sales of the drug began last November, and according to recent financial results posted by the company, Epidiolex has garnered substantial interest. Epidiolex sales totaled around $4.7 million in the last quarter, with more than 4,500 new patient enrollment forms during the first two months the drug was available. The positive results from Epidiolex sales were well received, and investors bid the company's shares higher after they were announced. Getting CBD products into the hands of consumers is also a focus for savvy companies looking to the future. Curaleaf Holdings Inc. (OTCQX: CURLF ) (CSE:CURA) recently announced a distribution deal with CVS Health Corp.